Novartis journeys to Mecca for Saudi vax effort

A Swiss-Saudi partnership has resulted in the opening of a vaccine plant in the holy city of Mecca. Novartis ($NVS) will provide vaccine manufacturing know-how to Arab Company for Pharmaceutical Products (Arabio), which owns the plant. Initial capacity will be 16 million doses per year when operation begins early next year, rising to 35 million vaccines. There's irony in the plant's location: vax-conscious Saudis request that haj pilgrims carry a certificate proving they've been vaccinated. Article

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.